Main Article Content
Acute Promyelocytic Leukemia, Differentiation Syndrome, Children, ATRA/ATO combination
The ATRA/ATO combination treatment of acute promyelocytic leukemia (APL) represents a paradigm of successful targeted and chemotherapy-free treatment in oncology. This therapeutic strategy is aimed at sparing patients from chemotherapy toxicity, while maintaining an excellent survival with a low risk of relapse. Main induction treatment-related complications are differentiation syndrome (DS) and hyperleukocytosis, which is related to DS and its severity. In the period December 2019 – December 2020, 8 children with newly diagnosed APL underwent induction therapy with ATRA/ATO in our center. In patients with WBC≥10x109/L two doses of Gemtuzumab Ozogamicin (GO) were added. In case of severe DS or hyperleukocytosis the differentiating agents were discontinued, high dose dexamethasone (DXM) and/or hydroxyurea (HU) were recommended. Five patients presented WBC<10x109/L ; all developed hyperleukocytosis and three also had DS and were initially treated with HU and DXM; due to unsatisfactory control of the symptoms GO was added in two of them.. One of the three patients with presenting WBC≥10x109/L, developed pseudotumor cerebri and another one DS. The supportive treatment was effective in all cases. Our experience shows that patients, treated with ATRA/ATO only, may develop marked hyperleukocytosis and severe DS, which may be unresponsive to discontinuation of differentiating agents and administration of HU and DXM and may benefit from the use of GO. Adequate intensive support therapy is crucial to rescue patients with severe DS.
2. Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018; 132(4): 405-412.
3. Strocchio L, Gurnari C, Santoro N, et al. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukemia. Br J Haematol. 2019; 185(2): 360-363.
4. Lo Coco F, Avvisati G, Vignetti M, et al. Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369: 111-121.
5. Rego EM, De Santis GC. Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011048.
6. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009; 113(4): 775-783.
7. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014; 123(18): 2777-2782.
8. Abaza Y, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated wih all-trans retinoic acid, arsenic trioxide and gentuzumab. Blood. 2017; 129(10): 1275-1283.
9. Garzia Spezza E, Brethon B, Petit A, et al. Tolerance to arsenic trioxide combined with all-trans retinoic acid in children with acute promyelocytic leukaemia in France. Br J Haematol. 2020; 188(1): 170-173.
10. Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the PETHEMA Group and review of the literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.
11. Camacho LH, Soignet SL, Chanel S, et al. leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia. J Clin Oncol. 2000; 18(13): 2620-2625.
12. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with AIDA protocols. Blood. 2012; 119(1): 49-54.